Allogeneic peptide-Major Histocompatibility Complex (pMHC) (allo-pMHC)

Allogeneic peptide-Major Histocompatibility Complex (pMHC) complexes are molecular structures on the surface of cells that present peptides to T cells (Murphy et al., Janeway's Immunobiology, 2016). In an allogeneic setting, these complexes consist of MHC molecules (Human Leukocyte Antigens or HLA in humans) that differ from the host's own genetic makeup (Felix & Allen, Nature Reviews Immunology, 2007). These complexes are the primary targets for T-cell receptors (TCRs) during the immune response to foreign tissue. The recognition of allo-pMHC by host T cells is the fundamental cause of acute and chronic transplant rejection (Wood & Goto, Transplantation, 2012). In hematopoietic stem cell transplantation, this interaction can lead to graft-versus-host disease (GvHD), where donor T cells attack the recipient's allo-pMHC-bearing cells (StatPearls, 2023). Conversely, the graft-versus-tumor effect relies on donor T cells recognizing allo-pMHC on malignant cells. Therapeutic interventions often target the TCR-pMHC interface or the resulting intracellular signaling to prevent immune-mediated damage (PubChem, 2024). Modern approaches include the development of TCR-like antibodies and CAR-T cells designed to specifically target or avoid these complexes. Monitoring these complexes through HLA typing and antibody screening is essential for clinical management in transplantation.

Other names

Allo-antigenAllogeneic MHCNon-self MHC-peptide complexAllo-HLAAllogeneic pMHC

T-cell receptor binding and subsequent immune signaling activation